Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 1726 AL 1740

Rare variants in PLXNA4 and Parkinson's disease

Schulte EC, Stahl I, Czamara D, Ellwanger DC, Eck S, Graf E, Mollenhauer B, Zimprich A, Lichtner P, Haubenberger D, Pirker W, Brücke T, Bereznai B, Molnar MJ, Peters A, Gieger C, Müller-Myhsok B, Trenkwalder C, Winkelmann J.

PLoS One. 2013 Nov 11;8(11):e79145. doi: 10.1371/journal.pone.0079145. eCollection 2013.

Dental management of Parkinson's disease: a case report

Katyayan PA, Katyayan MK, Nugala B.

N Y State Dent J. 2013 Aug-Sep;79(5):33-9.

Agomelatine treatment of major depressive disorder in Parkinson's disease: a case series

De Berardis D, Fornaro M, Serroni N, Olivieri L, Marini S, Moschetta FS, Srinivasan V, Assetta M, Valchera A, Salone A, Martinotti G, Onofrj M, Di Giannantonio M.

J Neuropsychiatry Clin Neurosci. 2013 Fall;25(4):343-5. doi: 10.1176/appi.neuropsych.12110286.

The prion hypothesis in Parkinson's disease: Braak to the future

Visanji NP, Brooks PL, Hazrati LN, Lang AE.

Acta Neuropathol Commun. 2013 May 8;1:2. doi: 10.1186/2051-5960-1-2.

ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies

Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM.

Acta Neuropathol Commun. 2013 May 9;1(1):11. doi: 10.1186/2051-5960-1-11.

The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease

Stutzbach LD, Xie SX, Naj AC, Albin R, Gilman S; PSP Genetics Study Group; Lee VM, Trojanowski JQ, Devlin B, Schellenberg GD.

Acta Neuropathol Commun. 2013 Jul 6;1:31. doi: 10.1186/2051-5960-1-31.

Promoter DNA methylation regulates progranulin expression and is altered in FTLD

Banzhaf-Strathmann J, Claus R, Mücke O, Rentzsch K, van der Zee J, Engelborghs S, De Deyn PP, Cruts M, van Broeckhoven C, Plass C, Edbauer D.

Acta Neuropathol Commun. 2013 May 13;1:16. doi: 10.1186/2051-5960-1-16.

Walking economy during cued versus non-cued treadmill walking in persons with Parkinson's disease

Gallo PM, McIsaac TL, Garber CE.

J Parkinsons Dis. 2013;3(4):609-19. doi: 10.3233/JPD-130217.

The role of oxidative stress in Parkinson's disease

Dias V, Junn E, Mouradian MM.

J Parkinsons Dis. 2013;3(4):461-91. doi: 10.3233/JPD-130230.

Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease

Beevers JE, Caffrey TM, Wade-Martins R.

Biochem Soc Trans. 2013 Dec;41(6):1503-8. doi: 10.1042/BST20130194.

α-Synuclein as a ferrireductase

Brown DR.

Biochem Soc Trans. 2013 Dec;41(6):1513-7. doi: 10.1042/BST20130130.

5-HT systems: emergent targets for memory formation and memory alterations

Meneses A.

Rev Neurosci. 2013;24(6):629-64. doi: 10.1515/revneuro-2013-0026.

Broad spectrum of hepatocyte inclusions in humans, animals, and experimental models

Strnad P, Nuraldeen R, Guldiken N, Hartmann D, Mahajan V, Denk H, Haybaeck J.

Compr Physiol. 2013 Oct;3(4):1393-436. doi: 10.1002/cphy.c120032.

Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems

Goldstein DS.

Compr Physiol. 2013 Oct;3(4):1569-610. doi: 10.1002/cphy.c130006.

[Focusing on improving the quality of life in patients with Parkinson's disease]

Fan DS.

Zhonghua Nei Ke Za Zhi. 2013 Jul;52(7):549-50.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias